BioCentury | Aug 31, 2009
Company News

Warner Chilcott, P&G deal

...is expected to close by year end, to dilute the company's FY10 EPS by $0.10-$0.12. JP Morgan Securities Inc....
BioCentury | Jul 20, 2009
Company News

Noven, Hisamitsu deal

...president and CEO of Noven. He will replace Peter Brandt, who is leaving the company. JP Morgan Securities Inc....
BioCentury | May 18, 2009
Company News

Epix diagnostic news

...Epix retained JP Morgan Securities Inc. to explore strategic alternatives, including a sale of the biotech's assets, potential mergers...
BioCentury | Sep 15, 2008
Company News

Myriad Genetics diagnostic, neurology, cancer news

...plans to complete a review of strategic alternatives by year end. Last month, Myriad retained JP Morgan Securities Inc....
BioCentury | Aug 25, 2008
Company News

Myriad Genetics diagnostic, neurology, cancer news

...Myriad retained JP Morgan Securities Inc. to explore strategic alternatives including potentially separating its molecular diagnostics and pharmaceutical businesses...
BioCentury | Apr 14, 2008
Company News

LifeCell, Kinetic Concepts deal

...Dec. 31, 2007, LifeCell had $91 million in cash and 2007 sales of $190.5 million. JP Morgan Securities Inc....
BioCentury | Dec 3, 2007
Company News

Agensys, Astellas deal

...April 2 & April 9). Montgomery & Co. LLC is financial advisor to Astellas, while JP Morgan Securities Inc....
Items per page:
1 - 7 of 7
BioCentury | Aug 31, 2009
Company News

Warner Chilcott, P&G deal

...is expected to close by year end, to dilute the company's FY10 EPS by $0.10-$0.12. JP Morgan Securities Inc....
BioCentury | Jul 20, 2009
Company News

Noven, Hisamitsu deal

...president and CEO of Noven. He will replace Peter Brandt, who is leaving the company. JP Morgan Securities Inc....
BioCentury | May 18, 2009
Company News

Epix diagnostic news

...Epix retained JP Morgan Securities Inc. to explore strategic alternatives, including a sale of the biotech's assets, potential mergers...
BioCentury | Sep 15, 2008
Company News

Myriad Genetics diagnostic, neurology, cancer news

...plans to complete a review of strategic alternatives by year end. Last month, Myriad retained JP Morgan Securities Inc....
BioCentury | Aug 25, 2008
Company News

Myriad Genetics diagnostic, neurology, cancer news

...Myriad retained JP Morgan Securities Inc. to explore strategic alternatives including potentially separating its molecular diagnostics and pharmaceutical businesses...
BioCentury | Apr 14, 2008
Company News

LifeCell, Kinetic Concepts deal

...Dec. 31, 2007, LifeCell had $91 million in cash and 2007 sales of $190.5 million. JP Morgan Securities Inc....
BioCentury | Dec 3, 2007
Company News

Agensys, Astellas deal

...April 2 & April 9). Montgomery & Co. LLC is financial advisor to Astellas, while JP Morgan Securities Inc....
Items per page:
1 - 7 of 7